🚀 VC round data is live in beta, check it out!
Largest Biopharmaceuticals Public Companies in the US
Benchmark revenue and EBITDA valuation multiples for public comps like
Eli Lilly, Johnson & Johnson, AbbVie, Merck and Amgen.
 | $955 | +6% | $853B | $889B | 12.7x | 27.4x | ||
| $241 | +54% | $581B | $609B | 6.3x | 17.1x | ||
| $212 | +9% | $376B | $438B | 7.0x | 16.5x | ||
| $123 | +44% | $303B | $338B | 5.2x | 12.3x | ||
| $356 | +22% | $192B | $237B | 6.4x | 12.7x | ||
| $142 | +33% | $176B | $192B | 6.5x | 12.1x | ||
| $27 | +12% | $155B | $205B | 3.3x | 8.5x | ||
| $59 | +18% | $121B | $158B | 3.3x | 9.1x | ||
| $447 | -12% | $114B | $109B | 8.9x | 20.1x | ||
| $768 | +28% | $81B | $75B | 5.1x | 14.4x | ||
| Pet Care+1 | $120 | -23% | $50B | $57B | 6.0x | 13.7x | |
| $789 | +22% | $49B | $45B | 9.5x | 32.3x | ||
| $321 | +22% | $43B | $41B | 9.8x | 49.6x | ||
| $25 | +16% | $36B | $32B | 5.8x | 45.4x | ||
| $160 | +122% | $34B | $34B | 37.0x | (32.6x) | ||
| $177 | +46% | $26B | $29B | 2.9x | 9.4x | ||
| $575 | +90% | $25B | $22B | 6.9x | 12.9x | ||
| $92 | -12% | $23B | $6B | 2.0x | (5.0x) | ||
| $48 | +47% | $21B | $28B | 8.7x | 9.3x | ||
| $51 | +80% | $20B | $16B | 8.0x | (5.6x) | ||
| $97 | +55% | $19B | $16B | 3.0x | 9.8x | ||
| $96 | +138% | $19B | $17B | 1153.2x | (13.3x) | ||
| $14 | +62% | $16B | $29B | 2.0x | 6.9x | ||
| $19 | -20% | $15B | $14B | 6304.6x | (14.6x) | ||
| $76 | +97% | $15B | $16B | 25.8x | (35.6x) | ||
| $62 | +46% | $14B | $14B | 42.3x | (409.4x) | ||
| $132 | +22% | $13B | $12B | 4.0x | 16.7x | ||
| $76 | +149% | $13B | $12B | 13.2x | (29.2x) | ||
| $198 | +69% | $12B | $15B | 3.5x | 14.3x | ||
| $524 | +57% | $12B | $11B | 10.3x | — | ||
| $45 | +16% | $12B | $11B | 4.6x | 10.8x | ||
| $23 | +147% | $12B | $15B | 3.2x | 16.5x | ||
| $56 | -12% | $11B | $10B | 3.0x | 14.3x | ||
| $66 | +377% | $9B | $9B | 13.7x | (91.7x) | ||
| $179 | +59% | $9B | $9B | 12.4x | (70.1x) | ||
| $17 | -44% | $9B | $17B | 1.5x | 7.6x | ||
| $320 | +759% | $9B | $8B | 5097.2x | (23.4x) | ||
| $62 | +72% | $9B | $7B | — | (7.6x) | ||
| $105 | +36% | $8B | $7B | 1810.5x | (16.8x) | ||
| $65 | +51% | $8B | $8B | 94.0x | (13.0x) | ||
| $67 | +9% | $8B | $10B | 6.7x | 12.5x | ||
| $7 | +198% | $8B | $8B | 57.3x | — | ||
| $258 | +52% | $8B | $7B | 15.9x | 37.7x | ||
| $182 | +195% | $7B | $7B | 960.2x | (75.1x) | ||
| $87 | +156% | $7B | $6B | 161.9x | (18.7x) | ||
| $115 | +77% | $7B | $6B | 155.1x | (25.8x) | ||
| $104 | +127% | $7B | $6B | 39.4x | (191.2x) | ||
| $87 | +120% | $6B | $6B | — | (18.8x) | ||
| $53 | +1493% | $6B | $5B | — | (43.7x) | ||
| $37 | +617% | $6B | $5B | 1124.8x | (17.5x) | ||
| $125 | +1019% | $6B | $6B | 379.9x | (31.8x) | ||
| $99 | +128% | $6B | $6B | 10.6x | (256.5x) | ||
| $635 | +3% | $6B | $7B | 2.5x | — | ||
| $86 | +32% | $6B | $6B | 25.6x | (29.1x) | ||
| $71 | +42% | $6B | $7B | 4.4x | 9.5x | ||
| $70 | +173% | $6B | $6B | 1455.6x | (359.9x) | ||
| $35 | +21% | $6B | $5B | 3.4x | 13.5x | ||
| $69 | +155% | $6B | $5B | 737.4x | (24.9x) | ||
| $49 | +49% | $6B | $5B | 1117.8x | (14.2x) | ||
| $35 | -24% | $6B | $6B | 8.1x | 35.6x | ||
| $19 | -- | $5B | $5B | 5.8x | 34.8x | ||
| $17 | +1089% | $5B | $5B | — | (34.0x) | ||
| $26 | +59% | $5B | $5B | — | (9.2x) | ||
| $41 | +112% | $5B | $5B | 5.4x | 335.0x | ||
| $92 | +319% | $5B | $4B | 2366.2x | — | ||
| $14 | +88% | $5B | $5B | 7.0x | 30.9x | ||
| $42 | -41% | $4B | $4B | 5.2x | 31.1x | ||
| $40 | +19% | $4B | $3B | 140.8x | (6.7x) | ||
| $206 | +87% | $4B | $4B | 14.2x | 31.7x | ||
| $4 | -- | $4B | $42B | — | — | ||
| $13 | +67% | $4B | $6B | 2.1x | 9.2x | ||
| $52 | +240% | $4B | $3B | — | (15.8x) | ||
| $35 | +21% | $4B | $3B | — | (8.0x) | ||
| $32 | +181% | $4B | $4B | 3.4x | 8.9x | ||
| $55 | +104% | $4B | $2B | 1352.7x | (8.0x) | ||
| $23 | +55% | $4B | $3B | 2.8x | 29.2x | ||
| $47 | +75% | $4B | $3B | 4.3x | 29.8x | ||
| $34 | +105% | $4B | $3B | — | (15.4x) | ||
| $40 | +189% | $4B | $4B | 12.9x | — | ||
| $18 | -48% | $3B | $3B | 2.5x | (33.9x) | ||
| $19 | +64% | $3B | $2B | — | (4.7x) | ||
| $63 | +508% | $3B | $3B | — | (21.4x) | ||
| $26 | +5% | $3B | $2B | 4.0x | 7.6x | ||
| $72 | +40% | $3B | $3B | 5.3x | — | ||
| $19 | +16% | $3B | $2B | 137.7x | (4.4x) | ||
| $25 | +65% | $3B | $3B | 7.2x | 93.0x | ||
| $52 | +59% | $3B | $3B | 3.6x | 17.1x | ||
| $21 | +1367% | $3B | $3B | 56.3x | (19.6x) | ||
| $41 | +75% | $3B | $2B | 195.8x | (7.1x) | ||
| $23 | +166% | $3B | $2B | 10.0x | (5.5x) | ||
| $23 | +454% | $3B | $3B | 134.3x | (9.3x) | ||
| $31 | +51% | $3B | $3B | 5.3x | 72.8x | ||
| $46 | +141% | $3B | $2B | — | (18.0x) | ||
| $31 | +54% | $3B | $2B | 12.5x | (9.4x) | ||
| $53 | -30% | $3B | $2B | 9.3x | 32.9x | ||
| $26 | +32% | $3B | $2B | 14.0x | (4.0x) | ||
| $15 | +350% | $3B | $2B | 169.3x | (7.4x) | ||
| $34 | +61% | $3B | $2B | 1151.3x | (7.3x) | ||
| $42 | +872% | $3B | $2B | — | (10.8x) | ||
| $67 | +36% | $3B | $2B | — | (7.3x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.